Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q3 2020 Earnings Presentation
8 slides from Puma Biotechnology's earnings presentation, Nov 5, 2020
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update November 5, 2020 Copyright 2020 Puma Biotechnology
Slide 2: Forward-Looking Safe Harbor Statement
Forward-Looking Safe Harbor Statement This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward–looking statements and are based on the cur
Slide 3: PUMA's Pharmacy and Distributor Network
PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria health Accredo CVS ONCO 360 Patients Optum / Diplomat Biologics Sites of Care Specialty Distributor Network (SD) Academic hospitals McKesson Community hospitals ASD/Oncology supply Physician Practices Cardina
Slide 4: ~$49.3 Million Net NERLYNX Revenue in Q3'2020
~$49.3 Million Net NERLYNX Revenue in Q3’2020 Quarterly Net Revenue (in $MM) 61.1 58.7 52.6 53.8 53.5 50.8 49.3 48.6 48.8 45.6 36.0 20.1 6.1 7 7 8 8 8 8 9 9 9 9 0 0 0 201 4'201 1'201 2'201 3'201 4'201 1'201 2'201 3'201 4'201 1'202 2'202 3'202 Q3' Q Q Q Q Q Q Q Q Q Q Q Q4 Copyright 2020 Puma Biotechn
Slide 5: ~3,600 Ex-factory Bottles were Sold in Q3'20
~3,600 Ex-factory Bottles were Sold in Q3’20 Bottles Sold (SP + SD) by Quarter 5,538 4,799 4,936 4,791 4,935 4,696 4,452 4,035 3,728 3,611 3,517 2,137 675 7 7 8 8 8 8 9 9 9 9 0 0 0 201 201 201 201 201 201 201 201 201 201 202 202 202 Q3' Q4' Q1' Q2' Q3' Q4' Q1' Q2' Q3' Q4' Q1' Q2' Q36' Includes Comme
Slide 6: ~33% of Patients in Q3'20 Started at a Reduced Dose
~33% of Patients in Q3’20 Started at a Reduced Dose % of Patients starting at reduced dose 32.8% 30.4% 30.8% 28.4% 19.0% 12.0% 10.7% 6.3% 6.8% 3.8% 2.5% 2.9% 1.8% 7 7 8 8 8 8 9 9 9 9 0 0 0 3' 201 4' 201 1' 201 2' 201 3' 201 4' 201 1' 201 2' 201 3' 201 4' 201 1' 202 2' 202 3' 202 6 Q Q Q Q Q Q Q Q Q
Slide 7: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory / Launch Milestones • March 2019 – Approved in Australia Australia / SE Asia • December 2019 -- Approved in Singapore • Q2/Q3 2020 - Approved in Brunei, Malaysia, New Zealand • Q1 2020 – Launched Israel • Q3 2020- Approved in metastati
Slide 8: Puma Biotechnology
Puma Biotechnology Earnings Call Commercial Update November 5, 2020 Copyright 2020 Puma Biotechnology 8